| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 61.29% | Oppenheimer | → $15 | Reiterates | Outperform → Outperform |
| 11/10/2023 | 61.29% | Stephens & Co. | $16 → $15 | Maintains | Overweight |
| 10/18/2023 | 39.78% | Morgan Stanley | $14 → $13 | Maintains | Overweight |
| 10/09/2023 | 61.29% | Oppenheimer | $16 → $15 | Maintains | Outperform |
| 08/14/2023 | 50.54% | Morgan Stanley | $13 → $14 | Maintains | Overweight |
| 08/14/2023 | 72.04% | Stephens & Co. | $14 → $16 | Maintains | Overweight |
| 08/14/2023 | 61.29% | Barclays | $14 → $15 | Maintains | Overweight |
| 07/19/2023 | 39.78% | Morgan Stanley | $13 → $13 | Reiterates | Overweight → Overweight |
| 05/17/2023 | 72.04% | Oppenheimer | $17 → $16 | Maintains | Outperform |
| 05/16/2023 | 61.29% | Stephens & Co. | → $15 | Reiterates | Overweight → Overweight |
| 04/18/2023 | 55.91% | Keefe, Bruyette & Woods | $15 → $14.5 | Maintains | Outperform |
| 04/13/2023 | 82.8% | Oppenheimer | $15 → $17 | Maintains | Outperform |
| 03/07/2023 | 61.29% | Keefe, Bruyette & Woods | $16 → $15 | Maintains | Outperform |
| 02/07/2023 | 61.29% | JP Morgan | $16 → $15 | Maintains | Overweight |
| 01/25/2023 | 82.8% | Oppenheimer | $15 → $17 | Maintains | Outperform |
| 01/24/2023 | 50.54% | Morgan Stanley | $15 → $14 | Maintains | Overweight |
| 12/19/2022 | 50.54% | Barclays | $15 → $14 | Maintains | Overweight |
| 10/10/2022 | 50.54% | Barclays | $15 → $14 | Maintains | Overweight |
| 08/31/2022 | 61.29% | Barclays | → $15 | Initiates Coverage On | → Overweight |
| 07/19/2022 | 61.29% | Morgan Stanley | $16 → $15 | Maintains | Overweight |
| 04/20/2022 | 72.04% | Morgan Stanley | $17 → $16 | Maintains | Overweight |
| 11/16/2021 | 82.8% | Stephens & Co. | → $17 | Initiates Coverage On | → Overweight |
| 11/15/2021 | 61.29% | UBS | → $15 | Initiates Coverage On | → Buy |
| 11/15/2021 | 93.55% | Morgan Stanley | → $18 | Initiates Coverage On | → Overweight |
| 11/15/2021 | 82.8% | JP Morgan | → $17 | Initiates Coverage On | → Overweight |
What is the target price for P10 (PX)?
The latest price target for P10 (NYSE: PX) was reported by Oppenheimer on November 13, 2023. The analyst firm set a price target for $15.00 expecting PX to rise to within 12 months (a possible 61.29% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for P10 (PX)?
The latest analyst rating for P10 (NYSE: PX) was provided by Oppenheimer, and P10 reiterated their outperform rating.
When is the next analyst rating going to be posted or updated for P10 (PX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of P10, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for P10 was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
Is the Analyst Rating P10 (PX) correct?
While ratings are subjective and will change, the latest P10 (PX) rating was a reiterated with a price target of $0.00 to $15.00. The current price P10 (PX) is trading at is $9.30, which is within the analyst's predicted range.